lifibrol has been researched along with 1-butanol in 16 studies
*1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1. [MeSH]
*1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 11 (68.75) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasibeder, H; Heibel, B; März, W; Schmidle, G; Seibel, K; Staab, HJ | 1 |
| Lang, G; Löser, R; Rattel, B; Schliack, M; Seibel, K | 1 |
| Blay, KH; Löser, R; Schliack, M; Seibel, K | 1 |
| Gross, W; Löser, R; März, W; Scharnagl, H; Schliack, M | 1 |
| Francom, SF; Hughes, GS; Jungbluth, GL; Locker, PK | 1 |
| Augustin, J; Elsässer, R; Gertz, B; Heil, M; Schmidt, C; Schwandt, P; Seibel, K | 1 |
| Bell, FP; St John, LC | 1 |
| Hsu, CY; Walters, RR | 1 |
| Bell, FP | 1 |
| Bell, FP; Feenstra, KL; Sanders, PE; Slatter, JG; Sun, EL; Ulrich, RG | 1 |
| Friedrich, I; Klima, B; Köster, W; März, W; Nuber, C; Sattler, A; Schäfer, JR; Steinmetz, A; Wieland, H; Winkler, K | 1 |
| Adams-Huet, B; Blumenschein, S; Carter, NB; Grundy, SM; Laeis, P; Lindenthal, B; Lutjohann, D; Simatupang, A; Vega, GL; von Bergmann, J; von Bergmann, K | 1 |
| Burger, A; Lettenbichler, A | 1 |
| Friedrich, I; Gierens, H; Klima, B; Köster, W; März, W; Nuber, C; Schaefer, JR; Scharnagl, H; Soufi, M; Wieland, H; Winkler, K | 1 |
| Gierens, H; Gross, W; Jeck, N; Löser, R; März, W; Nauck, M; Scharnagl, H; Schliack, M; Wieland, H | 1 |
| Berthold, HK; Gouni-Berthold, I; Sudhop, T; von Bergmann, K | 1 |
7 trial(s) available for lifibrol and 1-butanol
| Article | Year |
|---|---|
Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers.
Topics: Adolescent; Adult; Butanols; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxybenzoates; Hypolipidemic Agents; Male; Molecular Structure; Random Allocation; Reference Values | 1991 |
Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Bile Acids and Salts; Butanols; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxybenzoates; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Sex Factors; Sterols | 1995 |
Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia.
Topics: Anticholesteremic Agents; Butanols; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxybenzoates; Hypercholesterolemia; Lipids; Male; Middle Aged; Triglycerides | 1994 |
Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Butanols; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydroxybenzoates; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; Statistics, Nonparametric; Treatment Outcome | 1999 |
Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Butanols; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydroxybenzoates; Hypercholesterolemia; Hypolipidemic Agents; Male; Mevalonic Acid; Middle Aged; Simvastatin; Single-Blind Method; Triglycerides | 1999 |
HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia.
Topics: Adult; Apolipoprotein A-I; Butanols; Cholesterol, HDL; Humans; Hydroxybenzoates; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged | 2000 |
Lifibrol as a model compound for a novel lipid-lowering mechanism of action.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Butanols; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Humans; Hydroxybenzoates; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Pravastatin; Triglycerides; Young Adult | 2010 |
9 other study(ies) available for lifibrol and 1-butanol
| Article | Year |
|---|---|
The hypolipidemic effect of lifibrol during a long term treatment of pigs.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Aspartate Aminotransferases; Body Weight; Butanols; Cholesterol; Female; Hydroxybenzoates; Hypolipidemic Agents; Male; Sex Factors; Swine; Swine, Miniature; Time Factors; Triglycerides | 1990 |
Hypolipemic activity of K12.148 in rats, marmosets and pigs.
Topics: Animals; Butanols; Callithrix; Cholesterol; Cholesterol, LDL; Female; Hydroxybenzoates; Liver; Male; Rats; Rats, Inbred Strains; Swine; Triglycerides | 1989 |
A novel assay for cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography: demonstration that Lifibrol (K12.148) modulates the enzyme activity.
Topics: Animals; Butanols; Chickens; Chromatography, Ion Exchange; Cytosol; Hydroxybenzoates; Hydroxymethylglutaryl-CoA Synthase; Hypolipidemic Agents; Liver | 1995 |
Action of the new hypolipidemic agent lifibrol (K12.148) on lipid homeostasis in normal rats: plasma lipids, hepatic sterologenesis, and the fate of injected [14C]acetate.
Topics: Acetates; Animals; Butanols; Homeostasis; Hydroxybenzoates; Hypolipidemic Agents; In Vitro Techniques; Injections, Intraperitoneal; Lipid Metabolism; Lipids; Liver; Male; Rats; Rats, Sprague-Dawley; Reference Values; Sterols | 1993 |
Chiral assay methods for lifibrol and metabolites in plasma and the observation of unidirectional chiral inversion following administration of the enantiomers to dogs.
Topics: Administration, Oral; Animals; Autoanalysis; Biological Availability; Butanols; Chromatography, High Pressure Liquid; Dogs; Female; Hydroxybenzoates; Hypolipidemic Agents; Injections, Intravenous; Male; Robotics; Spectrophotometry, Ultraviolet; Stereoisomerism | 1994 |
Effect of the lipid-lowering drug lifibrol on lipid metabolism in rat macrophages and in atherosclerotic arteries from swine and WHHL rabbits, in vitro. Implications in atherogenesis.
Topics: Acetates; Animals; Aorta; Arteries; Arteriosclerosis; Butanols; Carbon Radioisotopes; Cholesterol; Hydroxybenzoates; Hyperlipidemias; Hypolipidemic Agents; Lipids; Macrophages, Peritoneal; Male; Oleic Acid; Oleic Acids; Rabbits; Rats; Rats, Sprague-Dawley; Swine | 1993 |
Biotransformation of lifibrol (U-83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture.
Topics: Animals; Anticholesteremic Agents; Biotransformation; Butanols; Cells, Cultured; Chromatography, High Pressure Liquid; Culture Media; Glycerides; Humans; Hydroxybenzoates; Liver; Male; Mass Spectrometry; Molecular Structure; Radioligand Assay; Rats; Rats, Wistar | 1996 |
Polymorphism and preformulation studies of lifibrol.
Topics: Anticholesteremic Agents; Butanols; Chemistry, Pharmaceutical; Drug Stability; Hydroxybenzoates | 2000 |
The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway.
Topics: Anticholesteremic Agents; Butanols; Cell Line; Cholesterol; Dose-Response Relationship, Drug; Humans; Hydroxybenzoates; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Prodrugs; Receptors, LDL; Sterols | 2000 |